As shown in Fig. 7 and Supplementary Figure 5, we found that maraviroc attenuates colon inflammation in this setting and reduced signs and symptoms of colitis, as well as the inflow of CD45+ cells into the LP. The gene discussed is PTPRC; the disease is digestive system cancer.